Medicenna Therapeutics Corp.

01/18/2022 | Press release | Distributed by Public on 01/18/2022 06:18

Phase 1/2 ABILITY study of MDNA11 remains on track for an update on additional safety pharmacokinetic (PK), and pharmacodynamic (PD) data in low-dose cohorts in Q1 2022 and[...]